A decade of follow-up data from the Abramson Cancer Center: a single dose of CAR T-cell therapy kept about a third of aggressive lymphoma patients, and nearly half w/slower-growing lymphoma, cancer-free. Results from Marco Ruella, Stephen Schuster and colleagues in NEJM: bit.ly/4rcEhpV
forbes.com
The Remarkable Success Of CAR T For Lymphoma 10 Years Later
Ten-year results show a single CAR T infusion can keep many patients with aggressive and slow-growing B-cell lymphomas cancer-free, pointing toward true long-term cures.
